New scope technique could simplify cancer monitoring after Kidney-Sparing surgery

NCT ID NCT07557563

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This pilot study will test whether a flexible scope inserted into the urinary tract (ureterorenoscopy) under local anesthesia is safe and feasible for monitoring upper tract urothelial cancer in 10 people who have had kidney-sparing surgery. The main goal is to see if the procedure can be completed successfully, with secondary checks on complications and hospital readmission rates. If it works, it may offer a less invasive way to watch for cancer recurrence.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

flexible ureterorenoscopy (a thin, flexible scope inserted into the urinary tract to look for cancer recurrence)

What this could lead to

If successful, this could offer a less invasive way to monitor for cancer return after kidney-sparing surgery, potentially avoiding more frequent hospital visits or more invasive procedures.

What could go wrong

This is a very small pilot study with only 10 participants, so results may not apply to everyone. The procedure is done under local anesthesia, which may cause discomfort or fail, and there is a risk of complications like infection or injury.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for UPPER TRACT UROTHELIAL CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal pelvis/ureter urothelial carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Prince of Wales Hospital

    Hong Kong, Hong Kong